Immuno-Interception for Patients with High-Risk Cancer.


Journal

Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409

Informations de publication

Date de publication:
06 2020
Historique:
received: 24 03 2020
revised: 30 03 2020
accepted: 03 04 2020
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 3 6 2021
Statut: ppublish

Résumé

Cancer immune-interception for prevention of recurrence in patients with high-risk familial cancer like Muir-Torre syndrome or Lynch syndrome using immune checkpoint blockade inhibitors is a promising approach. Albeit, as described in a case report by Pollak and colleagues in the April 2020 issue of

Identifiants

pubmed: 32487723
pii: 1940-6207.CAPR-20-0136
doi: 10.1158/1940-6207.CAPR-20-0136
doi:

Types de publication

Editorial Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

493-496

Commentaires et corrections

Type : CommentOn

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Asad Umar (A)

Cancer Prevention Fellowship, & Gastrointestinal & Other Cancers Research Group, Division of Cancer Prevention, NCI, Bethesda, Maryland. umara@mail.nih.gov.

Holli A Loomans-Kropp (HA)

Cancer Prevention Fellowship, & Gastrointestinal & Other Cancers Research Group, Division of Cancer Prevention, NCI, Bethesda, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH